^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Drug Class: | DOT1L inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
Excerpt:
...a t(4;11) cell line is sensitive to a combination of ABT-199 and DOT1L inhibitors. In addition, ABT-199 synergizes with standard induction-type therapy in a xenotransplant model, advocating for the introduction of ABT-199 into therapeutic regimens for MLL-rearranged leukemias.
DOI:
10.1016/j.celrep.2015.12.003
